---
title: "Azitra | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286350931.md"
datetime: "2026-05-14T03:24:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286350931.md)
  - [en](https://longbridge.com/en/news/286350931.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286350931.md)
---

# Azitra | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.25.

EBIT: As of FY2026 Q1, the actual value is USD -3.945 M, missing the estimate of USD -3.642 M.

Azitra, Inc. announced its financial results for the quarter ended March 31, 2026, as detailed in a press release incorporated by reference into a Form 8-K filing.

#### Operating Expenses

-   Research and Development (R&D) expenses increased to $1,560,565 for the quarter ended March 31, 2026, from $1,250,100 for the comparable period in 2025, representing an increase from $1.3 million to $1.6 million year-over-year.
-   General and Administrative (G&A) expenses increased to $2,373,359 for the quarter ended March 31, 2026, from $1,850,138 for the comparable period in 2025, representing an increase from $1.9 million to $2.4 million year-over-year.
-   Total operating expenses were $3,933,924 for the quarter ended March 31, 2026, compared to $3,100,238 for the comparable period in 2025.

#### Operating Profit / Loss

-   Loss from operations was -$3,933,924 for the quarter ended March 31, 2026, compared to -$3,100,238 for the comparable period in 2025.

#### Other Income (Expense)

-   Interest income was $14,719 for the quarter ended March 31, 2026, down from $37,164 for the comparable period in 2025.
-   Interest expense was -$3,411 for the quarter ended March 31, 2026, compared to -$1,293 for the comparable period in 2025.
-   Total other income was $6,684 for the quarter ended March 31, 2026, compared to $31,893 for the comparable period in 2025.

#### Net Loss

-   Net Loss was -$3,927,240 for the quarter ended March 31, 2026, compared to -$3,068,345 for the comparable period in 2025, reported as -$3.9 million for Q1 2026 compared to -$3.1 million for Q1 2025.

#### Cash and Cash Equivalents

-   Azitra, Inc. had $10,051,003 in cash and cash equivalents as of March 31, 2026, an increase from $2,068,083 as of December 31, 2025, reported as $10.1 million as of March 31, 2026.

#### Total Assets

-   Total assets were $12,126,804 as of March 31, 2026, compared to $5,025,386 as of December 31, 2025.

#### Total Liabilities

-   Total liabilities were $1,646,521 as of March 31, 2026, compared to $1,224,156 as of December 31, 2025.

#### Stockholders’ Equity

-   Total stockholders’ equity was $10,480,283 as of March 31, 2026, compared to $3,801,230 as of December 31, 2025.

#### Operational Highlights and Milestones

-   Azitra, Inc. added MD Anderson Cancer Center as a clinical site for its Phase 1⁄2 trial of ATR-04 for EGFRi-associated skin rash.
-   The company launched new protein and peptide programs for the cosmetic and cosmeceutical markets, utilizing proprietary filaggrin technologies.
-   A new U.S. patent covering ATR-12, the lead product candidate for Netherton syndrome, was secured.
-   Azitra, Inc. announced a poster presentation at the American Society of Gene and Cell Therapy Annual Meeting (ASGCT) 2026, highlighting ATR-01 preclinical data.
-   A private placement financing was priced for up to approximately $10.5 million, with an additional approximately $20.9 million upon exercise of warrants.

#### Outlook / Guidance

Azitra, Inc. anticipates several key milestones in 2026, including results from synthesized filaggrin ingredients for ATR-COSF in mid-2026, with a human cosmetic application study planned for Q3 2026. Topline data from the Phase 1b trial of ATR-12 for Netherton syndrome and the first cohort of the Phase 1⁄2 trial for ATR-04 are both expected in H2 2026. IND-enabling studies for the ATR-01 program will continue throughout 2026.

### Related Stocks

- [AZTR.US](https://longbridge.com/en/quote/AZTR.US.md)

## Related News & Research

- [Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates | AZTR Stock News](https://longbridge.com/en/news/286262344.md)
- [Azitra reports Q1 2026 net loss $3.9M, cash $10.1M; advances ATR-12, ATR-04 trials](https://longbridge.com/en/news/286239732.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Acenta Group delays Q1 interim report release to May 29, 2026](https://longbridge.com/en/news/287031560.md)